Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant

Archives of Surgery

Volumn 138, Issue 8, 2003, Pages 879-883

  Calhoun, Kristine E ^b   Pommier, Rodney F ^a   Muller, Patrick ^b   Fletcher, William S ^b   Toth Fejel, SuEllen ^a   Alberty, Roger E ^b   Kebebew, Electron ^b   Goodnight, James E ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; PRASTERONE SULFATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL DIVISION; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 0042532160     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.138.8.879     Document Type: Conference Paper

References (16)

1. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the overview. J Clin Oncol. 1993;11:580-585.
2. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13:513-529.
3. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-825.
4. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994;54:408-414.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
6. McClelland RA, Barrow D, Madden T-A, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology. 2001;142:2776-2788.
7. Howell A, Dowsett M. Recent advances in endocrine therapy of breast cancer. BMJ. 1997;315:863-866.
8. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
9. Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(suppl 12):4402s-4410s.
10. Favoni RE, de Cupis A. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends Pharmacol Sci. 1998;19:406-415.
11. Morris KT, Toth-Fejel S, Schmidt J, et al. High DHEA-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery. 2001;130(6):947-953.
12. Calhoun K, Pommier R, Cheek J, et al. The effect of high dehydroepiandrosterone-sulfate levels on tamoxifen blockade and breast cancer progression. Am J Surg. 2003;185:411-415.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
14. Robertson JFR. Faslodex (ICI 182,780), a novel estrogen receptor downregulator: future possibilities in breast cancer. J Steroid Biochem Mol Biol. 2001;79:209-212.
15. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739-6746.
16. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res. 2001;7(suppl 12):4369s-4375s.